Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 40
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Anim Sci J ; 89(7): 1033-1039, 2018 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-29766599

RESUMEN

The objective of the present study was to evaluate the effectiveness of enrofloxacin (ERFX) as a second-line antibiotic for treatment of acute Escherichia coli (E. coli) mastitis. Forty-two cows with naturally occurring acute E. coli mastitis were enrolled. On the first day of treatment (day 0), empirically selected antibiotics (oxytetracycline: n = 32, kanamycin: n = 10) were administered. Although systemic signs improved in 10 cows (first-line group), the signs remained unchanged or worsened in 32 cows on day 1, including two cows that were found dead. The 30 surviving cows were randomly assigned to second-line groups constituting an ERFX group (n = 19) or a control group (n = 11) that was treated with other antibiotics. Response to each treatment was evaluated by measuring clinical signs from day 0 to day 3, subsequent quarter milk recovery, and the 60-day survival rate. Appetite on day 3 was significantly better in the ERFX group compared to the control group. No significant differences were observed in the 60-day survival rate or the subsequent milk recovery between the ERFX group and the control group. Thus, the use of ERFX as a second-line antibiotic for the treatment of acute E. coli mastitis could induce a rapid appetite recovery.


Asunto(s)
Antibacterianos/administración & dosificación , Enfermedades de los Bovinos/tratamiento farmacológico , Infecciones por Escherichia coli , Fluoroquinolonas/administración & dosificación , Mastitis/tratamiento farmacológico , Mastitis/microbiología , Mastitis/veterinaria , Retratamiento/métodos , Enfermedad Aguda , Animales , Apetito , Bovinos , Enfermedades de los Bovinos/fisiopatología , Progresión de la Enfermedad , Quimioterapia Combinada , Enrofloxacina , Femenino , Kanamicina/administración & dosificación , Mastitis/fisiopatología , Oxitetraciclina/administración & dosificación , Factores de Tiempo , Insuficiencia del Tratamiento , Resultado del Tratamiento
2.
J Assoc Physicians India ; 64(5): 90-92, 2016 05.
Artículo en Inglés | MEDLINE | ID: mdl-27735167

RESUMEN

A 22 year-old lady with multi-drug-resistant pulmonary tuberculosis was on Kanamycin, Cycloserine, Ethionamide, Pyrazinamide and Moxifloxacin since more than two months. She presented with muscle cramps and carpopedal spasm. Investigation revealed hypokalemia and metabolic alkalosis. She also had hypomagnesemia, hypochloremia and hypocalciuria. Serum urea and creatinine levels were normal. Patient was treated with intravenous and oral potassium chloride. Kanamycin was stopped. Metabolic alkalosis and hypokalemia improved gradually over one month. Biochemical parameters were like Gitelman's syndrome but it reversed with stoppage of Kanamycin. Gitelman-like syndrome with Kanamycin toxicity has not been reported in literature previously.


Asunto(s)
Alcalosis/inducido químicamente , Antibacterianos/uso terapéutico , Antituberculosos/uso terapéutico , Hipopotasemia/inducido químicamente , Kanamicina/efectos adversos , Potasio/administración & dosificación , Tuberculosis Pulmonar/tratamiento farmacológico , Adulto , Antibacterianos/administración & dosificación , Antituberculosos/administración & dosificación , Antituberculosos/efectos adversos , Cicloserina/administración & dosificación , Cicloserina/efectos adversos , Etionamida/administración & dosificación , Etionamida/efectos adversos , Femenino , Fluoroquinolonas/administración & dosificación , Fluoroquinolonas/efectos adversos , Humanos , Kanamicina/administración & dosificación , Moxifloxacino , Calambre Muscular/etiología , Potasio/sangre , Pirazinamida/administración & dosificación , Pirazinamida/efectos adversos , Resultado del Tratamiento , Tuberculosis Resistente a Múltiples Medicamentos , Tuberculosis Pulmonar/diagnóstico , Tuberculosis Pulmonar/microbiología
3.
Trials ; 15: 353, 2014 Sep 09.
Artículo en Inglés | MEDLINE | ID: mdl-25199531

RESUMEN

BACKGROUND: In contrast to drug-sensitive tuberculosis, the guidelines for the treatment of multi-drug-resistant tuberculosis (MDR-TB) have a very poor evidence base; current recommendations, based on expert opinion, are that patients should be treated for a minimum of 20 months. A series of cohort studies conducted in Bangladesh identified a nine-month regimen with very promising results. There is a need to evaluate this regimen in comparison with the currently recommended regimen in a randomized controlled trial in a variety of settings, including patients with HIV-coinfection. METHODS/DESIGN: STREAM is a multi-centre randomized trial of non-inferiority design comparing a nine-month regimen to the treatment currently recommended by the World Health Organization in patients with MDR pulmonary TB with no evidence on line probe assay of fluoroquinolone or kanamycin resistance. The nine-month regimen includes clofazimine and high-dose moxifloxacin and can be extended to 11 months in the event of delay in smear conversion. The primary outcome is based on the bacteriological status of the patients at 27 months post-randomization. Based on the assumption that the nine-month regimen will be slightly more effective than the control regimen and, given a 10% margin of non-inferiority, a total of 400 patients are required to be enrolled. Health economics data are being collected on all patients in selected sites. DISCUSSION: The results from the study in Bangladesh and cohorts in progress elsewhere are encouraging, but for this regimen to be recommended more widely than in a research setting, robust evidence is needed from a randomized clinical trial. Results from the STREAM trial together with data from ongoing cohorts should provide the evidence necessary to revise current recommendations for the treatment for MDR-TB. TRIAL REGISTRATION: This trial was registered with clincaltrials.gov (registration number: ISRCTN78372190) on 14 October 2010.


Asunto(s)
Antituberculosos/administración & dosificación , Proyectos de Investigación , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico , Tuberculosis Pulmonar/tratamiento farmacológico , Bangladesh , Protocolos Clínicos , Clofazimina/administración & dosificación , Esquema de Medicación , Quimioterapia Combinada , Etambutol/administración & dosificación , Fluoroquinolonas/administración & dosificación , Humanos , Isoniazida/administración & dosificación , Kanamicina/administración & dosificación , Moxifloxacino , Protionamida/administración & dosificación , Pirazinamida/administración & dosificación , Factores de Tiempo , Resultado del Tratamiento , Tuberculosis Resistente a Múltiples Medicamentos/diagnóstico , Tuberculosis Resistente a Múltiples Medicamentos/microbiología , Tuberculosis Pulmonar/diagnóstico , Tuberculosis Pulmonar/microbiología
4.
Int J Pharm ; 463(2): 170-6, 2014 Mar 25.
Artículo en Inglés | MEDLINE | ID: mdl-23871740

RESUMEN

In this paper, we report the synthesis, characterization (FT-IR, XRD, BET, HR-TEM) and bioevaluation of a novel γ-aminobutiric acid/silica (noted GABA-SiO2 or γ-SiO2) hybrid nanostructure, for the improved release of topical antibiotics, used in the treatment of Staphylococcus aureus infections. GABA-SiO2 showed IR bands which were assigned to Si-O-Si (stretch mode). The XRD pattern showed a broad peak in the range of 18-30° (2θ), indicating an amorphous structure. Based on the BET analysis, estimations about surface area (438.14 m²/g) and pore diameters (4.76 nm) were done. TEM observation reveals that the prepared structure presented homogeneity and an average size of particles not exceeding 10nm. The prepared nanostructure has significantly improved the anti-staphylococcal activity of bacitracin and kanamycin sulfate, as demonstrated by the drastic decrease of the minimal inhibitory concentration of the respective antibiotics loaded in the GABA-SiO2 nanostructure. These results, correlated with the high biocompatibility of this porous structure, are highlighting the possibility of using this carrier for the local delivery of the antimicrobial substances in lower active doses, thus reducing their cytotoxicity and side-effects.


Asunto(s)
Antibacterianos/química , Portadores de Fármacos/química , Nanoestructuras/química , Dióxido de Silicio/química , Staphylococcus aureus/efectos de los fármacos , Ácido gamma-Aminobutírico/química , Administración Tópica , Antibacterianos/administración & dosificación , Bacitracina/administración & dosificación , Bacitracina/química , Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Portadores de Fármacos/administración & dosificación , Humanos , Kanamicina/administración & dosificación , Kanamicina/química , Pruebas de Sensibilidad Microbiana , Microscopía Electrónica de Transmisión , Nanoestructuras/ultraestructura , Espectroscopía Infrarroja por Transformada de Fourier , Infecciones Cutáneas Estafilocócicas/tratamiento farmacológico , Staphylococcus aureus/crecimiento & desarrollo , Propiedades de Superficie , Difracción de Rayos X
5.
Nanoscale ; 5(1): 246-52, 2013 Jan 07.
Artículo en Inglés | MEDLINE | ID: mdl-23154667

RESUMEN

A hybrid bactericidal material, gold nanorod-covered kanamycin-loaded hollow SiO(2) (HSKAu(rod)) nanocapsules, is constructed. The hybrid material combines the features of a chemical drug with photothermal physical sterilization which decreases the dosage of broad-spectrum antibiotic and the physical damage of biological systems. Hollow SiO(2) nanocapsules are used as carriers for drug delivery. The nanocapsules load a model drug, kanamycin, and are covered with gold nanorods to avoid drug leakage and realize photothermal treatment. The sterilizing effect on the bacterial strain is investigated by incubating E. coli BL21 with the hybrid nanocapsules and irradiating under near-infrared light (NIR) for 20 min. A bactericidal effect, i.e., a sterilizing rate of 53.47%, is achieved for the HSKAu(rod) nanocapsules under NIR irradiation, with respect to a net sum sterilizing rate of 34.49% for the individual components of the HSKAu(rod) nanocapsules, e.g., carrier nanocapsules, chemical sterilization of kanamycin and physical sterilization due to the gold nanorods under NIR irradiation. It is demonstrated that the combination of chemical drug and physical sterilization results in an obvious synergistic effect and makes the sterilization more effective. This novel hybrid has great potential as an adjuvant therapeutic alternative material for sterilization or even for the control of disease.


Asunto(s)
Escherichia coli/efectos de los fármacos , Oro/uso terapéutico , Hipertermia Inducida/métodos , Kanamicina/administración & dosificación , Nanocápsulas/efectos de la radiación , Fotoquimioterapia/métodos , Dióxido de Silicio/química , Antibacterianos/administración & dosificación , Antibacterianos/química , Supervivencia Celular/efectos de los fármacos , Terapia Combinada/métodos , Difusión , Escherichia coli/citología , Kanamicina/química , Nanocápsulas/química , Nanocápsulas/ultraestructura , Porosidad
6.
J Dairy Sci ; 95(6): 3448-53, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22612980

RESUMEN

A combination of kanamycin and cefalexin was licensed in Europe in 2008 to treat bovine clinical mastitis. Preliminary broth and disk clinical breakpoints for this antibiotic combination have been proposed for Staphylococcus aureus, Streptococcus dysgalactiae, Streptococcus uberis, and Escherichia coli. This study indicates that these proposed breakpoints also hold for coagulase-negative staphylococci (CNS), a group of bacteria frequently isolated in milk samples from cows with clinical mastitis. The data show that clinical bovine mastitis isolates of CNS from Europe have a high degree of susceptibility to the kanamycin/cefalexin combination, with minimal resistance to either agent alone. The use of the available kanamycin and cefalexin combination disk for testing the susceptibility of bovine mastitis isolates of Staph. aureus, Strep. uberis, Strep. dysgalactiae, and E. coli is also reliable for use in the testing of CNS, as disk results correlated with broth minimum inhibitory concentrations. The study reports, for the first time, the approved Clinical Laboratory Standards Institute quality control ranges for the kanamycin/cefalexin combination and wild-type cutoff values for major bacterial pathogens implicated in bovine mastitis.


Asunto(s)
Cefalexina/uso terapéutico , Kanamicina/uso terapéutico , Mastitis Bovina/tratamiento farmacológico , Infecciones Estafilocócicas/veterinaria , Staphylococcus aureus/efectos de los fármacos , Animales , Bovinos , Cefalexina/administración & dosificación , Pruebas Antimicrobianas de Difusión por Disco/veterinaria , Combinación de Medicamentos , Escherichia coli/efectos de los fármacos , Infecciones por Escherichia coli/tratamiento farmacológico , Infecciones por Escherichia coli/microbiología , Infecciones por Escherichia coli/veterinaria , Femenino , Kanamicina/administración & dosificación , Mastitis Bovina/microbiología , Pruebas de Sensibilidad Microbiana/veterinaria , Infecciones Neumocócicas/tratamiento farmacológico , Infecciones Neumocócicas/microbiología , Infecciones Neumocócicas/veterinaria , Infecciones Estafilocócicas/tratamiento farmacológico , Infecciones Estafilocócicas/microbiología , Streptococcus pneumoniae/efectos de los fármacos
7.
J Assoc Res Otolaryngol ; 10(4): 525-44, 2009 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19644644

RESUMEN

Significant sensory hair cell loss leads to irreversible hearing and balance deficits in humans and other mammals. Future therapeutic strategies to repair damaged mammalian auditory epithelium may involve inserting stem cells into the damaged epithelium, inducing non-sensory cells remaining in the epithelium to transdifferentiate into replacement hair cells via gene therapy, or applying growth factors. Little is currently known regarding the status and characteristics of the non-sensory cells that remain in the deafened auditory epithelium, yet this information is integral to the development of therapeutic treatments. A single high-dose injection of the aminoglycoside kanamycin coupled with a single injection of the loop diuretic furosemide was used to kill hair cells in adult mice, and the mice were examined 1 year after the drug insult. Outer hair cells are lost throughout the entire length of the cochlea and less than a third of the inner hair cells remain in the apical turn. Over 20% and 55% of apical organ of Corti support cells and spiral ganglion cells are lost, respectively. We examined the expression of several known support cell markers to investigate for possible support cell dedifferentiation in the damaged ears. The support cell markers investigated included the microtubule protein acetylated tubulin, the transcription factor Sox2, and the Notch signaling ligand Jagged1. Non-sensory epithelial cells remaining in the organ of Corti retain acetylated tubulin, Sox2 and Jagged1 expression, even when the epithelium has a monolayer-like appearance. These results suggest a lack of marked SC dedifferentiation in these aged and badly damaged ears.


Asunto(s)
Sordera/patología , Células Laberínticas de Soporte/citología , Envejecimiento/patología , Animales , Biomarcadores/análisis , Biomarcadores/metabolismo , Proteínas de Unión al Calcio/análisis , Proteínas de Unión al Calcio/biosíntesis , Diferenciación Celular , Sordera/inducido químicamente , Sordera/metabolismo , Diuréticos/administración & dosificación , Diuréticos/efectos adversos , Furosemida/administración & dosificación , Furosemida/efectos adversos , Células Ciliadas Auditivas/efectos de los fármacos , Células Ciliadas Auditivas/metabolismo , Células Ciliadas Auditivas/patología , Humanos , Péptidos y Proteínas de Señalización Intercelular/análisis , Péptidos y Proteínas de Señalización Intercelular/biosíntesis , Proteína Jagged-1 , Kanamicina/administración & dosificación , Kanamicina/efectos adversos , Células Laberínticas de Soporte/efectos de los fármacos , Células Laberínticas de Soporte/metabolismo , Proteínas de la Membrana/análisis , Proteínas de la Membrana/biosíntesis , Ratones , Inhibidores de la Síntesis de la Proteína/administración & dosificación , Inhibidores de la Síntesis de la Proteína/efectos adversos , Factores de Transcripción SOXB1/análisis , Factores de Transcripción SOXB1/biosíntesis , Proteínas Serrate-Jagged , Ganglio Espiral de la Cóclea/efectos de los fármacos , Ganglio Espiral de la Cóclea/patología , Tubulina (Proteína)/análisis , Tubulina (Proteína)/biosíntesis
8.
Intern Med ; 47(14): 1363-6, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18628588

RESUMEN

Campylobacter coli (C. coli) is a rare pathogen of bacteremia, but in immunocompromised hosts, C. coli occasionally causes bacteremia which can be refractory to antibiotic treatment. We report a case of C. coli bacteremia in a patient with X-linked agammaglobulinemia. Bacteremia relapsed repeatedly in spite of treatment with combined intravenous antibiotics. C. coli was observed in the biopsy specimens from the intestinal mucosa, suggesting intestinal carriage and reservoir of recurring infection. The addition of oral kamamycin with intravenous antibiotics was successful in eradicating C. coli from the blood and intestine.


Asunto(s)
Antibacterianos/administración & dosificación , Infecciones por Campylobacter/tratamiento farmacológico , Campylobacter coli , Kanamicina/administración & dosificación , Administración Oral , Adulto , Agammaglobulinemia/complicaciones , Infecciones por Campylobacter/diagnóstico , Quimioterapia Combinada , Disentería/tratamiento farmacológico , Endocarditis/tratamiento farmacológico , Humanos , Infusiones Intravenosas , Masculino , Pruebas de Sensibilidad Microbiana , Osteomielitis/tratamiento farmacológico
9.
Probl Tuberk Bolezn Legk ; (2): 31-8, 2007.
Artículo en Ruso | MEDLINE | ID: mdl-17419333

RESUMEN

A suspension of multidrug resistant clinical Mycobacterium tuberculosis (MBT) strain, at a concentration of 1 x 10(8) microbes per ml, resistant to streptomycin (S), rifampicin (R), isoniazid (I), and kanamycin (K), was in vitro treated for 60 minutes with dissolved ozone (pO3) at a concentration of 0.5-4 microg/ml). Then it was placed in the Lowenstein-Jensen media containing various concentrations of S, I, R, and K. Following 3 months, drug susceptibility was determined by the number of cultured colonies and MBT was used to prepare a suspension at the same concentration, which was again treated with pO3 by the same procedure and placed to the media containing the drugs. A session was thrice repeated. After each pO3 treatment, MBT resistance to I decreased and it completely disappeared after triple treatment. Each pO3 treatment caused a reduction in MBT resistance to R, but it was high (640 microg/ml). After double pO3 treatment MBT resistance to S decreased, but it was recovered after its third ozone treatment. All pO3-untreated control cultures showed a growth of more than 100 colonies. Sixty-eight BALC/s mice were in vivo inoculated via intravenous injections of the clinical MBT strain resistant to S, I, R, and K. The mice were divided into 5 groups: 1) intact mice; 2) those inoculated and untreated; 3) those treated with 1; 4) those treated with I and peritoneally given pO3, 0.5-4 microg/ml); and 5) those given pO3. The animals began dying at month 4 of inoculation. By month 5, all mice, other than intact and pO3-treated ones, died. Passage of MBT from the month by month 4 showed a reduction in their resistance to I in the groups treated with pO3. When the mice were treated with I alone, damages to their livers and spleens were greater than when they were untreated. With co-administration of I and pO3, the damage was least. Treatment provoked a rapid change of MBT to granular and L-forms and MBT was undetectable in its typical form after 1-2-month therapy. The altered MBT formed an untypical histological pattern of tuberculous inflammation in mice in the presence of characteristic cellular cooperation. Clinical studies indicated that 1-6-month concurrent use of chemotherapy and pO3 in patients with drug-resistant tuberculosis eliminated drug resistance of isolated MBT to one of the drugs (I, R, K) in 97.3%, MBT became at once susceptible to I, R, and K in 47.2%. I and/or R were successfully used in the treatment of more than a third of the patients. The studies have demonstrated that most patients with drug-resistant pulmonary tuberculosis can be treated with the most effective drugs provided that systemic intravenous injection of pO3 is made.


Asunto(s)
Antituberculosos/farmacología , Antituberculosos/uso terapéutico , Mycobacterium tuberculosis/efectos de los fármacos , Ozono/farmacología , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico , Tuberculosis Pulmonar/tratamiento farmacológico , Adolescente , Adulto , Animales , Antibacterianos/administración & dosificación , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Antibióticos Antituberculosos/administración & dosificación , Antibióticos Antituberculosos/farmacología , Antibióticos Antituberculosos/uso terapéutico , Antituberculosos/administración & dosificación , Modelos Animales de Enfermedad , Farmacorresistencia Bacteriana Múltiple/efectos de los fármacos , Quimioterapia Combinada , Femenino , Humanos , Inyecciones Intravenosas , Isoniazida/administración & dosificación , Isoniazida/farmacología , Isoniazida/uso terapéutico , Kanamicina/administración & dosificación , Kanamicina/farmacología , Kanamicina/uso terapéutico , Masculino , Ratones , Ratones Endogámicos BALB C , Persona de Mediana Edad , Mycobacterium tuberculosis/aislamiento & purificación , Ozono/administración & dosificación , Radiografía Torácica , Rifampin/administración & dosificación , Rifampin/farmacología , Rifampin/uso terapéutico , Estreptomicina/administración & dosificación , Estreptomicina/farmacología , Estreptomicina/uso terapéutico , Factores de Tiempo , Resultado del Tratamiento , Tuberculosis Pulmonar/diagnóstico por imagen
10.
Kekkaku ; 81(1): 19-23, 2006 Jan.
Artículo en Japonés | MEDLINE | ID: mdl-16479997

RESUMEN

A 59-year-old man who had just completed therapy for tuberculosis, fell down in sauna and was admitted to a hospital. As acid-fast bacilli were positive (Gaffky 2) in sputum and residual cavity was shown in the right upper lobe on chest X-ray, he was transferred to our hospital. In spite of starting antituberculous chemotherapy, small nodular shadows appeared diffusely and were changed into ground-glass appearance on chest X-ray. The trans-bronchial-lung-biopsy revealed alveolitis mainly composed of lymphocyte infiltration with non-caseous epithelioid cell granulomas and organization which are likely to appear in hypersensitivity pneumonitis. As the acid-fast bacilli were identified as Mycobacterium avium, clarithromycin and kanamycin were added to the chemotherapy, but no improvement was observed in clinical feature. Corticosteroid therapy was further added and clinical feature improved immediately. Although we did not examine the presence of Mycobacterium avium in the water of sauna bath, we suspected this case as Hot Tub Lung based on clinical features and the response to treatment.


Asunto(s)
Complejo Mycobacterium avium/aislamiento & purificación , Infección por Mycobacterium avium-intracellulare/diagnóstico , Tuberculosis Pulmonar/diagnóstico , Alveolitis Alérgica Extrínseca , Claritromicina/administración & dosificación , Diagnóstico Diferencial , Quimioterapia Combinada , Humanos , Kanamicina/administración & dosificación , Masculino , Persona de Mediana Edad , Infección por Mycobacterium avium-intracellulare/tratamiento farmacológico , Infección por Mycobacterium avium-intracellulare/microbiología , Infección por Mycobacterium avium-intracellulare/transmisión , Prednisolona/administración & dosificación , Baño de Vapor/efectos adversos , Resultado del Tratamiento , Tuberculosis Pulmonar/tratamiento farmacológico , Tuberculosis Pulmonar/microbiología , Tuberculosis Pulmonar/transmisión , Microbiología del Agua
11.
J Nat Prod ; 67(9): 1604-7, 2004 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-15387672

RESUMEN

Naturally occurring phyllodulcin (1) was orally administered to rats to investigate its metabolic fate. Urinary metabolites were analyzed by three-dimensional HPLC. Phyllodulcin-3'-O-sulfate (2), phyllodulcin-3'-O-beta-glucuronide (3), 2-[2-(3,4-dihydroxyphenyl)ethyl]-6-hydroxybenzoic acid (4), and one novel bibenzyl derivative, 2-[2-(3-hydroxy-4-methoxyphenyl)ethyl]-6-hydroxybenzoic acid (5), together with thunberginol G (6) and hydrangenol (7) were isolated from the phyllodulcin-treated urine. 1 was extensively metabolized to 4-6 by a rat fecal suspension after incubation for 24 h. Urinary excretion of 4-6 in rats administered phyllodulcin orally was substantially reduced when the rats were treated with antibiotics to suppress their intestinal flora. On the other hand, the incubation of 1 with rat liver S-9 mix showed the presence of 7 together with 4 and 5.


Asunto(s)
Cumarinas/metabolismo , Administración Oral , Animales , Bacitracina/administración & dosificación , Benzopiranos/química , Benzopiranos/aislamiento & purificación , Cumarinas/administración & dosificación , Cumarinas/farmacocinética , Heces/química , Hydrangea/química , Isocumarinas , Kanamicina/administración & dosificación , Hígado/metabolismo , Masculino , Plantas Medicinales/química , Ratas , Ratas Sprague-Dawley , Sulfatiazoles/administración & dosificación , Tetraciclina/administración & dosificación , Orina/química
12.
Probl Tuberk Bolezn Legk ; (7): 32-5, 2004.
Artículo en Ruso | MEDLINE | ID: mdl-15379039

RESUMEN

The outcomes of treatment were analyzed in 56 patients with ever-progressive multidrug-resistant pulmonary tuberculosis who had been long isolating Mycobacterium tuberculosis (MBT). The patients were divided into 2 groups. In the study group (n = 36), 75% isolated MBT resistant to streptomycin (S), isoniazid (I), rifampicin (R), and kanamycin (K). In this connection, 41.7% of them received only 2 second-line antituberculous drugs and 27.8% took 3 drugs. The control group (n = 20) was comparable with the study group in the rate of bacterial isolation and in the drug resistance of the causative agent. In addition to chemotherapy (CT), dissolved ozone (pO3) was intravenously injected to the patients of the study group twice a week. They received a total of 12 to 55 infusions. Four-month addition of pO3 infusions to CT eliminated the resistance of isolated MBT to I and/or R. MBT became susceptible to I in 38.9% of the patients, R in 16.7%, and to K in 11.2%. By month 4, the isolated MBT became susceptible to I, R, and K in 47.2%. The mechanisms responsible for lowering drug resistance in MBT are discussed. The clinical example shows that patients with multidrug-resistant tuberculosis may be treated with first-line drugs provided that systemic intravenous injection of pO3 is performed.


Asunto(s)
Antibacterianos/uso terapéutico , Antituberculosos/uso terapéutico , Mycobacterium tuberculosis/efectos de los fármacos , Ozono/administración & dosificación , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico , Tuberculosis Pulmonar/tratamiento farmacológico , Adolescente , Adulto , Antibacterianos/administración & dosificación , Antibacterianos/farmacología , Antibióticos Antituberculosos/administración & dosificación , Antibióticos Antituberculosos/farmacología , Antibióticos Antituberculosos/uso terapéutico , Antituberculosos/administración & dosificación , Antituberculosos/farmacología , Farmacorresistencia Bacteriana Múltiple , Femenino , Humanos , Inyecciones Intravenosas , Isoniazida/administración & dosificación , Isoniazida/farmacología , Isoniazida/uso terapéutico , Kanamicina/administración & dosificación , Kanamicina/farmacología , Kanamicina/uso terapéutico , Masculino , Persona de Mediana Edad , Mycobacterium tuberculosis/aislamiento & purificación , Rifampin/administración & dosificación , Rifampin/farmacología , Rifampin/uso terapéutico , Estreptomicina/administración & dosificación , Estreptomicina/farmacología , Estreptomicina/uso terapéutico , Factores de Tiempo , Resultado del Tratamiento , Tuberculosis Resistente a Múltiples Medicamentos/microbiología , Tuberculosis Pulmonar/microbiología
13.
Probl Tuberk Bolezn Legk ; (3): 21-6, 2004.
Artículo en Ruso | MEDLINE | ID: mdl-15338895

Asunto(s)
Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Antibióticos Antituberculosos/farmacología , Antibióticos Antituberculosos/uso terapéutico , Antituberculosos/farmacología , Antituberculosos/uso terapéutico , Mycobacterium tuberculosis/efectos de los fármacos , Tuberculosis Pulmonar/tratamiento farmacológico , Antibacterianos/administración & dosificación , Antibióticos Antituberculosos/administración & dosificación , Antituberculosos/administración & dosificación , Clortetraciclina/administración & dosificación , Clortetraciclina/farmacología , Clortetraciclina/uso terapéutico , Farmacorresistencia Bacteriana , Quimioterapia Combinada , Femenino , Humanos , Infusiones Intravenosas , Inyecciones Intramusculares , Isoniazida/administración & dosificación , Isoniazida/farmacología , Isoniazida/uso terapéutico , Kanamicina/administración & dosificación , Kanamicina/farmacología , Kanamicina/uso terapéutico , Masculino , Pruebas de Sensibilidad Microbiana , Mutación , Mycobacterium tuberculosis/genética , Mycobacterium tuberculosis/fisiología , Pirazinamida/administración & dosificación , Pirazinamida/farmacología , Pirazinamida/uso terapéutico , Recurrencia , Rifampin/administración & dosificación , Rifampin/farmacología , Rifampin/uso terapéutico , Estreptomicina/administración & dosificación , Estreptomicina/farmacología , Estreptomicina/uso terapéutico , Factores de Tiempo , Tuberculosis Pulmonar/microbiología
14.
Hear Res ; 71(1-2): 125-36, 1993 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-8113131

RESUMEN

Behavioral detection thresholds were obtained from four starlings before, during, and after 11 days of subcutaneous injections of kanamycin. Birds were operantly conditioned to respond to pure-tones ranging in frequency from 0.25 kHz to 7 kHz using the method of constant stimuli and were tested daily for 141 days after the first injection of aminoglycoside. All four birds sustained hearing losses greater than 60 dB at frequencies from 4 kHz to 7 kHz by the end of the 11 day injection schedule. Two birds had a slight shift in threshold at 3 kHz. No change in threshold occurred for any of the birds at lower frequencies. Recovery of detection thresholds began soon after the injections ceased and continued for approximately 50 days. In all four birds there was some degree of permanent hearing loss: 5 dB to 15 dB at frequencies between 4 kHz and 6 kHz, and approximately 25 dB at 7 kHz. Scanning electron microscopy (SEM) was performed at 0 and 5 days post-injection in a separate group of starlings given the same injection schedule. Hair cell loss and damage was observed across the basal 34% to 36% of the basilar papilla. SEM in two behaviorally tested birds sacrificed 142 days after the first injection showed that there was regeneration of hair cells to populate the previously damaged region, but that disorientation of stereocilia bundles in the basal third of the basilar papilla was common. The other two behaviorally tested birds were treated with kanamycin again for 16 days beginning at 142 days after the first injection. Thresholds shifted again, but less than during the first dosing period. SEM of these birds' basilar papillae showed less hair cell loss than observed in the birds given only a single, 11 day dosing of kanamycin. This result suggests that birds may be less susceptible to the ototoxic effects of kanamycin in repeated treatments. In all four birds, the degree and position of damage observed with SEM corresponded with the extent and frequency of hearing loss.


Asunto(s)
Umbral Auditivo/fisiología , Membrana Basilar/ultraestructura , Células Ciliadas Auditivas/citología , Kanamicina/toxicidad , Estimulación Acústica , Animales , Umbral Auditivo/efectos de los fármacos , Membrana Basilar/efectos de los fármacos , Aves , Relación Dosis-Respuesta a Droga , Células Ciliadas Auditivas/efectos de los fármacos , Células Ciliadas Auditivas/fisiología , Inyecciones Subcutáneas , Kanamicina/administración & dosificación , Microscopía Electrónica de Rastreo , Regeneración
15.
Klin Khir (1962) ; (2): 6-8, 1993.
Artículo en Ruso | MEDLINE | ID: mdl-10912051

RESUMEN

In the experiment on mongrel dogs, the absorption of indigo carmine dye after its retroperitoneal administration with 10% dimexide solution into the lymphatic and venous systems was studied. More rapid delivery of a dye into the portal system, including the cases with portal hypertension, and into the lymphatic system was established. A method for retroperitoneal administration of antibiotics with 10% dimexide solution for prevention and treatment of purulent-septic complications in patients with acute appendicitis has been developed. The method was used in 120 patients, the result of treatment is good.


Asunto(s)
Apendicitis/complicaciones , Sepsis/prevención & control , Enfermedad Aguda , Animales , Antibacterianos/administración & dosificación , Apendicitis/tratamiento farmacológico , Terapia Combinada , Dimetilsulfóxido/administración & dosificación , Perros , Evaluación Preclínica de Medicamentos , Quimioterapia Combinada , Humanos , Hipertensión Portal/tratamiento farmacológico , Carmin de Índigo/administración & dosificación , Kanamicina/administración & dosificación , Peritonitis/tratamiento farmacológico , Peritonitis/etiología , Peritonitis/prevención & control , Sepsis/tratamiento farmacológico , Sepsis/etiología
16.
Artículo en Ruso | MEDLINE | ID: mdl-2168658

RESUMEN

Antiseptic gelatin sponges with kanamycin and gentamicin, which were studied in experiments on animals and used in the clinic, are a reliable measure for the prevention of suppuration in craniocerebral surgery in planned operations and in combination with debridement in penetrating injury of the skull and brain. For therapeutic purposes, local application of the agents is effective in focal suppurative processes in the skull and brain after surgical debridement of the purulent focus (abscess of the brain, osteomyelitis of the skull, etc.).


Asunto(s)
Encefalopatías/prevención & control , Encéfalo/cirugía , Gentamicinas/administración & dosificación , Kanamicina/administración & dosificación , Infecciones Estafilocócicas/prevención & control , Infección de la Herida Quirúrgica/prevención & control , Animales , Antisepsia/métodos , Encefalopatías/etiología , Lesiones Encefálicas/complicaciones , Lesiones Encefálicas/cirugía , Preparaciones de Acción Retardada , Perros , Evaluación de Medicamentos , Evaluación Preclínica de Medicamentos , Gelatina , Humanos , Conejos , Infecciones Estafilocócicas/etiología , Infección de la Herida Quirúrgica/etiología , Heridas no Penetrantes/complicaciones , Heridas no Penetrantes/cirugía , Heridas Penetrantes/complicaciones , Heridas Penetrantes/cirugía
17.
Br J Urol ; 62(2): 140-4, 1988 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-3136820

RESUMEN

An open, prospective, randomised, comparative study of "Trisdine" and kanamycin-colistin bladder instillations in reducing significant bacteriuria during intermittent urethral catheterisation was conducted. Trisdine is an aqueous solution of chlorhexidine gluconate 0.01% with added ethylenediaminetetra-acetic acid disodium salt and TRIS buffer at final concentrations of 1.34 mMoles and 0.01 Molar respectively. All patients (15 males and 3 females) admitted with acute spinal cord trauma and bladder involvement requiring intermittent catheterisation for more than 5 days during a 12-month period were studied. There was no significant difference in the mean incidence of significant bacteriuria during intermittent catheterisation in the 7 males who had kanamycin-colistin bladder instillations compared with the 8 males who had Trisdine instillations. A comparison could not be made in the females because there were only 3 patients. Because Trisdine is more stable at ambient temperatures, is less likely to select antibiotic-resistant bacteria and is less expensive, it is concluded that Trisdine is preferable to kanamycin-colistin solution for bladder instillations during intermittent catheterisation.


Asunto(s)
Antiinfecciosos Urinarios/uso terapéutico , Bacteriuria/prevención & control , Clorhexidina/análogos & derivados , Colistina/uso terapéutico , Ácido Edético/uso terapéutico , Kanamicina/uso terapéutico , Traumatismos de la Médula Espinal/terapia , Trometamina/uso terapéutico , Cateterismo Urinario/efectos adversos , Enfermedad Aguda , Adolescente , Adulto , Antiinfecciosos Urinarios/administración & dosificación , Bacteriuria/etiología , Clorhexidina/uso terapéutico , Ensayos Clínicos como Asunto , Colistina/administración & dosificación , Combinación de Medicamentos/uso terapéutico , Femenino , Humanos , Kanamicina/administración & dosificación , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Distribución Aleatoria
18.
Hear Res ; 32(1): 1-10, 1988 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-3350770

RESUMEN

The incidence and severity of audiogenic seizures in kanamycin (KM)-treated rat pups, from a Wistar strain which is inherently seizure-resistant, was analyzed as a function of (a) postnatal age at the time of KM injection (i.p.) and (b) KM dosage. The vigor of the pinna reflex response on postnatal day (PND) 28 was correlated with (a) age at the time of injection, (b) dosage and (c) individual audiogenic seizure severity scores on PND 28 or PND 32. The data indicate that PNDs 9-12 are the developmental period when the rat has its greatest sensitivity to induction of susceptibility to audiogenic seizures by KM. The pinna reflex data suggest that cochlear vulnerability to KM intoxication is also greatest during this period. The optimum dosage for the induction of susceptibility was 100 mg/kg X 4 days. Use of higher doses resulted in a reduction of both incidence and severity of audiogenic seizures. The pinna reflex generally exhibited a supranormal vigor in animals having the most severe seizures. The behavioral attributes of induced audiogenic seizures at postnatal ages of 28 and 32 days are described and discussed.


Asunto(s)
Kanamicina/efectos adversos , Convulsiones/inducido químicamente , Estimulación Acústica , Factores de Edad , Animales , Cóclea/efectos de los fármacos , Susceptibilidad a Enfermedades , Relación Dosis-Respuesta a Droga , Oído Externo/fisiología , Kanamicina/administración & dosificación , Ratas , Ratas Endogámicas , Reflejo , Convulsiones/etiología
20.
Pediatr Res ; 19(11): 1152-5, 1985 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-3906546

RESUMEN

The conventional antimicrobial therapy of gram-negative infection in the newborn is the combination of ampicillin and an aminoglycoside, usually gentamicin or kanamycin. Although gentamicin and kanamycin have been used interchangeably, efficacies of the two drugs have not been carefully compared. In addition, the contribution of ampicillin to the outcome of neonatal gram-negative meningitis is controversial. We evaluated the activity of gentamicin and kanamycin alone and in combinations with ampicillin in vitro and in vivo against a K1 Escherichia coli strain. In vitro, the E. coli strain was relatively sensitive to ampicillin, gentamicin, and kanamycin, with the minimal inhibitory and minimal bactericidal concentrations of 2 and 4, 2 and 2, and 4 and 8 micrograms/ml, respectively. Checkerboard determinations of minimal inhibitory and minimal bactericidal concentrations of drug combinations exhibited an indifferent response for both ampicillin + gentamicin and ampicillin + kanamycin. However, in vivo studies using an experimental E. coli bacteremia and meningitis model in newborn rats suggested that gentamicin was more effective than kanamycin. This was shown by more rapid bacterial clearance from the blood, a decreased incidence of meningitis in bacteremic animals, and improved survival. Furthermore, the addition of ampicillin improved the outcome of kanamycin, but not gentamicin, suggesting that the contribution of ampicillin may vary depending on the type of aminoglycoside used. These findings suggest that kanamycin is less effective than gentamicin in vivo against E. coli and should be used in combination with ampicillin to achieve an outcome comparable to that of gentamicin in this model of E. coli infection.


Asunto(s)
Ampicilina/administración & dosificación , Infecciones por Escherichia coli/tratamiento farmacológico , Gentamicinas/administración & dosificación , Kanamicina/administración & dosificación , Animales , Animales Recién Nacidos , Evaluación Preclínica de Medicamentos , Quimioterapia Combinada , Meningitis/tratamiento farmacológico , Ratas , Ratas Endogámicas , Sepsis/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA